Detection of residual disease using Folate-FITC enhanced optical imaging in ovarian carcinoma

Completed

• Conditions: ovarian carcinoma; 10029903; residual disease; 10038597

• Registration Number: NL-OMON33039
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

female > 21 yrs of age; operable ovarian carcinoma

Exclusion Criteria

Pregnant women, significant renal, cardiac, or pulmonary disease (ASA III-IV), History of iodine allergy or anaphylactic reactions to insect bites or medication, presence or history of hyperthyroidism

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Intra-operative detection of ovarian cancer by a folate-FITC enhanced optical<br /><br>imaging device, in which visual inspection in combination with routine<br /><br>histology is considered the golden standard for the presence of tumour tissue.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Presence of fluorescent residual disease after intended radical resection by<br /><br>visual observation alone (proven bij biopsy)</p><br>